Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 14, 2023

Lenvatinib Plus Pembrolizumab for Previously Treated Advanced Endometrial Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
J. Clin. Oncol 2023 Apr 14;[EPub Ahead of Print], V Makker, N Colombo, AC Herráez, BJ Monk, H Mackay, AD Santin, DS Miller, RG Moore, S Baron-Hay, I Ray-Coquard, K Ushijima, K Yonemori, YM Kim, EM Guerra Alia, UA Sanli, S Bird, R Orlowski, J McKenzie, C Okpara, G Barresi, D Lorusso

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading